BIIB - Acorda to regain global commercialization rights to FAMPYRA by Jan 2025
2024-01-11 08:15:15 ET
More on Acorda Therapeutics
- Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript
- Acorda Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Acorda Therapeutics GAAP EPS of -$7.16, revenue of $27.72M
- Financial information for Acorda Therapeutics
For further details see:
Acorda to regain global commercialization rights to FAMPYRA by Jan 2025